专利号:US-11274164-B2 优先权日:2017-02-07 标 题 :Method for the preparation of sulfobutylether beta cyclodextrin sodium 发明人:PULLAGURLA MANIK REDDY; PITTA BHASKAR REDDY; NAMANA SURESH BABU; NAGARAPU RADHA; RANGISETTY JAGADEESH BABU 权利人:BIOPHORE INDIA PHARMACEUTICALS PVT LTD 摘要:The present invention relates to an improved method for the synthesis of sulfobutylether beta cyclodextrin sodium and to provide an amorphous form of sulfobutylether beta cyclodextrin sodium having a 1,4-butane sultone content less than 0.5 ppm. The present invention further provides sulfobutylether beta cyclodextrin sodium containing less than 35 IU/g of Bacterial endotoxins.
专利号:WO-2025125811-A1 优先权日:2023-12-12 标题:Heterocyclic compounds and their use for the treatment of neurological disorders 发明人:PLOWRIGHT ALLEYN THOMAS; PFEIFFER THOMAS; MÄRCHER-RØRSTED EMIL; DUCKWORTH EDWARD JOSEPH 权利人:ONTRACK THERAPEUTICS LTD 摘要:The present invention relates to novel synthetic compounds of Formula (I) and (II) related to naturally occurring flavonoids such as 7,8-dihydroxyflavone (7,8-DHF). The invention further relates to the method of synthesis, the use of these compounds as research tools and their use as pharmaceuticals.
专利号:WO-2022061120-A1 优先权日:2020-09-18 标题 :Solid dispersions containing amorphous nintedanib, their synthesis and use thereof 发明人:ELLENBERGER DANIEL; MILLER DAVE 权利人:DISPERSOL TECHNOLOGIES LLC 摘要:The invention relates to solid dispersions containing amorphous nintedanib and methods making such solid dispersions. The invention also relates to pharmaceutical compositions containing such solid dispersions. The invention further relates to methods of making and administering such pharmaceutical compositions. The pharmaceutical compositions of the invention are useful in the treatment of oncological diseases, immunologic: diseases, or pathological conditions involving an immunologic component, or fibrotic diseases.
1: Kim SH, Kwon JC, Park C, Han S, Yim DS, Choi JK, Cho SY, Lee HJ, Park SH, Choi SM, Choi JH, Yoo JH, Lee DG, Lee JW. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016 Jun 21. doi: 10.1111/myc.12517. [Epub ahead of print] doi: 10.1016/j.carbpol.2016.04.115. Epub 2016 Apr 28. doi: 10.1128/AAC.01493-15. Epub 2015 Aug 10. 5: Shityakov S, Puskás I, Pápai K, Salvador E, Roewer N, Förster C, Broscheit JA. Sevoflurane-Sulfobutylether-β-Cyclodextrin Complex: Preparation, Characterization, Cellular Toxicity, Molecular Modeling and Blood-Brain Barrier Transport Studies. Molecules. 2015 Jun 3;20(6):10264-79. doi: 10.3390/molecules200610264. doi: 10.1016/j.ejpb.2015.05.019. Epub 2015 May 30. doi: 10.1111/acem.12657. Epub 2015 Apr 23. 8: Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, Teitelbaum I. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015 Feb 3;19:32. doi: 10.1186/s13054-015-0753-8.